Abstract
Gastroesophageal reflux disease (GERD) is a common disorder. The most effective treatment for GERD is a proton pump inhibitor (PPI). The aim of this study was to find out the available on the Bulgarian pharmaceutical market PPI and to conduct a cost-minimization analysis for the treatment of reflux esophagitis with PPI. The results showed that in Bulgaria the PPI were presented by 53 pharmaceutical products with international nonproprietary names (INN) omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. In the cost-minimization analysis, only those drugs and dosage forms were chosen for which therapeutic equivalence had been proven in clinical trials. Drugs with INN omeprazole 20 mg daily, lansoprazole 30 mg daily, pantoprazole 40 mg daily and esomeprazole 20 mg daily a for 8-week treatment had a comparable efficacy of 85%, 86%, 89% and 87%, respectively. The cost of treatment varied to a high extent: from 7,17 BGN to 40,48 BGN. The most cost-saving treatment of GERD in our country can be achieved by drug products of pantoprazole. In conclusion, a cost-saving therapy of esophagitis in GERD might be conducted by a proper choice of the drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
